HSBC Bank Plc : Form 8.5 (EPT/RI) - London Stock Exchange

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HSBC Bank Plc : Form 8.5 (EPT/RI) - London Stock Exchange Group Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a) Name of exempt principal trader: HSBC BANK PLC
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:      Use a separate form for each offeror/offeree   London Stock Exchange Group Plc
(c) Name of the party to the offer with which exempt principal trader is connected: Deutsche Boerse AG
(d) Date dealing undertaken: 14 th November 2016
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? Yes-  Deutsche Boerse AG

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

Class of relevant security Purchases/ sales   Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
  Ordinary Shares   Purchase   2,351   2,813.00 p   2,813.00 p
  Ordinary Shares   Sale   2,351   2,813.00 p   2,813.00 p

(b)        Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
         

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"
    None  

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
  None
Date of disclosure: 15 th November 2016
Contact name: Ray Onrubia
Telephone number: 0207 088 2000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors of Sage Therapeutics Have Chance to Join Lawsuit

Updated Category News Views 88

Introduction to the Class Action Lawsuit Attention, investors! There's an important opportunity arising for shareholder litigation against Sage Therapeutics, Inc. The legal firm Bronstein, Gewirtz & Grossman, LLC is officially notifying individuals who have invested in Sage Therapeutics about a class action lawsuit that has now been filed. If you have faced substantial...

Continue Reading
FARO Technologies Revolutionizes 3D Metrology with Leap ST

Updated Category News Views 105

FARO Technologies Enhances 3D Metrology with Leap ST FARO Technologies, Inc. (NASDAQ: FARO) is pushing the boundaries of handheld scanning technology with the introduction of the Leap ST. This launch marks a significant expansion of FARO's product portfolio, positioning the company among the few firms offering a comprehensive range of portable 3D metrology solutions. Leap...

Continue Reading
Strong Financial Performance and Growth Strategies at TORM PLC

Updated Category News Views 181

TORM PLC Reports Robust Q3 2025 Financial Results TORM PLC has demonstrated remarkable resilience and adaptability, reporting its strongest quarterly results in 2025. This achievement underscores the effectiveness of TORM's integrated operating model, as highlighted by the CEO. The company continues to prioritize creating long-term value for its shareholders while...

Continue Reading
Manhattan Associates Faces Legal Challenges Amid Shareholder Losses

Updated Category News Views 304

Manhattan Associates Faces Legal Challenges Following Shareholder Loss In recent developments, Manhattan Associates, Inc. (NASDAQ: MANH) is under scrutiny as a class action lawsuit has been filed against the company. This action comes after an alarming drop in shareholder value, amounting to over $4 billion. The lawsuit is pivotal as it involves allegations of misleading...

Continue Reading
BioLife Solutions Announces Upcoming Financial Results

Updated Category News Views 91

BioLife Solutions to Share Key Financial Insights BioLife Solutions, Inc. (NASDAQ: BLFS), a pioneering developer and supplier of bioproduction products and services specializing in cell and gene therapies, is gearing up for a significant event. The company plans to release its financial results for the third quarter of 2024 after market hours on November 12, 2024. This is...

Continue Reading